ArticleFrontiers in public health2025
Endometriosis-related infertility in China: analysis of the global burden of disease study 2021.
Article in Frontiers in public health, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Endometriosis-Associated Infertility in China: Epidemiological Trends, Future Projection, and Real-World Clinical Insights.International journal of women's health · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: Utilizing the Global Burden of Disease (GBD) 2021 dataset, this study analyzed temporal trends (1990-2021) and age-period-cohort patterns of endometriosis-related infertility burden in China versus globally. By employing joinpoint regression and APC modeling, we aimed to identify key epidemiological shifts and disparities, thereby providing evidence-based insights for optimizing health service planning and resource allocation strategies targeting endometriosis-related infertility. Methods: Using age-standardized prevalence rates (ASPR) of endometriosis-related infertility (1990-2021) from the GBD 2021 database, we analyzed Chinese females aged 15-49 years. Joinpoint regression identified significant trend changes in ASPR, while age-period-cohort (APC) modeling decomposed effects into age, period, and birth cohort dimensions using 5-year intervals. Results: In 2021, the age-standardized prevalence rate (ASPR) of patients with endometriosis-related primary infertility in China was 280.63 per 100,000 population (95% UI: 115.61 to 616.39). The percentage change in ASPR for endometriosis-associated primary infertility in China between 1990 and 2021 was -23.35% (95% UI: -10.52% to -32.68%) above the global level -29.61% (95% UI: -37.19% to -24.79%). In 2021, the ASPR of patients with endometriosis-associated secondary infertility in China was 1849.35 per 100,000 population (95% UI: 1104.61 to 2931.00). The percentage change of endometriosis-associated secondary between 1990 and 2021 ASPR in China was -38.16% (95% UI: -43.81% to -31.53%), below the global level -24.70% (95% UI: -27.99% to -21.11%). Conclusion: The ASPR of endometriosis-related female infertility in China and globally declined between 1990 and 2021. This indicates that China has attained significant progress in addressing and managing endometriosis-related female infertility. However, the overall burden of endometriosis-related female infertility remains substantial and requires continued attention.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.